You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

IMPACT Trial Logo

The IMPACT Study

InforMing the PAthway of COPD Treatment

Trelegy▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol 92/55/22 mcg) is indicated as maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of a ICS and a LABA[1]

Relvar ▼ Ellipta (fluticasone furoate/vilanterol 92/22 mcg) is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy[2]

Anoro▼ Ellipta (umeclidinium/vilanterol 55/22 mcg) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD[3]

IMPACT Summary Infographic

References:

  1. Trelegy Ellipta SmPC.
  2. Relvar Ellipta SmPC.
  3. Anoro Ellipta SmPC.

Anoro, Ellipta, Relvar and Trelegy are a registered trademark of the GlaxoSmithKline group of companies